ATXI OTC
Avenue Therapeutics, Inc.
1W: -18.5%
1M: -28.5%
3M: +23.5%
YTD: -40.6%
1Y: -43.4%
3Y: -99.2%
5Y: -100.0%
$0.41
+0.05 (+13.22%)
Weekly Expected Move ±37.9%
$0
$0
$0
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
18 relationships18
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-12-13
Earliest Filing
2026-02-23
Latest Filing
partner: 9
investor: 5
acquirer: 2
target: 2
Counterparties (Filed by ATXI)
18 relationshipsCompanies named in ATXI's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Duke University | — | partner | Avenue Therapeutics entered into a license agreement to obtain exclusive worldwide rights to certain patents and know-ho | 2026-02-23 | View |
| Axsome Therapeutics, Inc. | AXSM | acquirer | Acquired 100% of Baergic Bio, Inc. and received commercial rights to AXS-17. | 2025-11-12 | View |
| AnnJi Pharmaceutical Co., Ltd. | — | partner | Licensee and counterparty in a terminated license agreement and program transfer for AJ201 intellectual property rights. | 2025-04-30 | View |
| H.C. Wainwright & Co. LLC | — | partner | Entered into an At the Market Offering Agreement to sell shares of Avenue Therapeutics, Inc. | 2024-05-13 | View |
| Fortress Biotech, Inc. | FBIOP | investor | Acquired 767,085 shares of common stock in a private placement transaction. | 2023-09-08 | View |
| Fortress Biotech, Inc. | FBIOP | acquirer | Transferred majority ownership of Baergic to Avenue Therapeutics in exchange for assumption of liabilities. | 2022-11-08 | View |
| Baergic Bio, Inc. | — | target | Clinical-stage pharmaceutical company acquired by Avenue Therapeutics. | 2022-11-08 | View |
| InvaGen Pharmaceuticals Inc. | — | investor | Previous equity investor whose shares were repurchased and agreements terminated as a closing condition. | 2022-11-08 | View |
| AstraZeneca | AZN | partner | Original developer of Baergic's principal asset, BAER-101. | 2022-11-08 | View |
| Aegis Capital Corp. | — | partner | Entered into an Underwriting Agreement for the Company's public offering of Units and Pre-funded Units. | 2022-10-12 | View |
| VStock Transfer, LLC | — | partner | Entered into a Warrant Agent Agreement to act as warrant agent for the Company. | 2022-10-12 | View |
| Fortress Biotech, Inc. | FBIOP | partner | Parent company transferring ownership of subsidiary Baergic Bio, Inc. to Avenue Therapeutics, Inc. | 2022-05-16 | View |
| Baergic Bio, Inc. | — | target | Private subsidiary of Fortress Biotech, Inc. being transferred to Avenue Therapeutics, Inc. | 2022-05-16 | View |
| InvaGen Pharmaceuticals Inc. | — | investor | Minority stockholder agreeing to have its shares repurchased and terminate agreements. | 2022-05-16 | View |
| The Nasdaq Stock Market LLC | — | partner | Listing authority notified of delisting due to audit committee composition issues. | 2022-05-16 | View |
| Abeona Therapeutics Inc. | ABEO | investor | Company on whose board Faith L. Charles serves (mentioned in director biography). | 2022-05-16 | View |
| Entera Bio Ltd. | ENTX | investor | Company on whose board Faith L. Charles previously served (mentioned in director biography). | 2022-05-16 | View |
| Aegis Capital Corp. | — | partner | Representative of underwriters in the underwriting agreement for the common stock offering. | 2021-12-13 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-02-23 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-31 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-18 | Shareholder Nominations; Other Events | View | |
| 2025-11-12 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-04-30 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Completion o | Agreement Acquisition | View |
| 2025-03-17 | Notice of Delisting or Transfer | View | |
| 2025-03-07 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-29 | Notice of Delisting or Transfer | View | |
| 2024-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-27 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-08-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-05-23 | Other Events | View | |
| 2024-05-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-05-13 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2024-05-01 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
| 2024-03-15 | Other Events | View | |
| 2024-03-08 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-02-23 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2024-01-12 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-01-08 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR